Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZLD-2
- Development stage
- Unknown
- Lead developer
- Sichuan University
01
Overview
ZLD-2: sourced facts only. name: "ZLD-2, the most promising compound, exhibited potent inhibitory activity against EZH2 and BRD4." [PMID:36774555]; target: "ZLD-2, the most promising compound, exhibited potent inhibitory activity against EZH2 and BRD4." [PMID:36774555]; target: "ZLD-2, the most promising compound, exhibited potent inhibitory activity against EZH2 and BRD4." [PMID:36774555]; developer: "Department of Anesthesiology, West China Hospital, Sichuan University, Chengdu 610000, China." [PMID:36774555]; stage: "In vivo, ZLD-2 exhibited antitumor activity in a BxPC-3 mouse xenograft model, whereas GSK126 promoted tumor growth." [PMID:36774555]
02
Targets
BRD4 (Bromodomain-containing protein 4)EZH2 (Histone-lysine N-methyltransferase EZH2)
Beyond the preview
Go deeper on ZLD-2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZLD-2.